[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.87.119.171. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 629
Citations 0
In This Issue of JAMA
August 16, 2016

Highlights

JAMA. 2016;316(7):685-687. doi:10.1001/jama.2015.14432

In a randomized, placebo- and active-controlled trial involving 2463 postmenopausal women with osteoporosis, Miller and colleagues compared treatment with subcutaneous abaloparatide—a novel selective activator of the parathyroid hormone type 1 receptor—with placebo or open-label teriparatide for the prevention of new vertebral fractures. The authors report that compared with placebo, use of abaloparatide reduced the risk of new vertebral and nonvertebral fractures over 18 months. In an Editorial, Cappola and Shoback discuss treatment to reduce fracture risk among postmenopausal women.

First Page Preview View Large
First page PDF preview
First page PDF preview
×